Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Dale buys straight from the ATM, we won't know about it until the Form 4 is released.
Dale can start buying tomorrow. I believe his buying was usually done mid-morning around 10:30am or 11am in the past.
The 10-Q only required they disclose the ATM sells through June 30th. Declaring shares sold through August 10th would indicate that Dale is buying since they need to disclose up-to-date insider information for Dale to buy.
Humanigen Reports Second Quarter 2022 Financial Results
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Reports-Second-Quarter-2022-Financial-Results/default.aspx
Looks like the 10-Q might come Monday. That means Dale will be able to buy on Wednesday. My guess is that the 10-Q release will give a 5% or 10% bump to the share price on the anticipation of Dale buying. If Dale buys on Wednesday, the share price could go north quickly.
Dale will almost surely buy a ton of shares when he gets the chance in early August. They might even rush the the release of the quarterly report so that he can buy in as quickly as possible. He will be allowed to buy more shares two days after the quarterly report is released.
Past 3rd Quarter Report Dates
8-12-21
8-14-20
8-12-19
8-09-18
8-10-17
Hopefully, we see data soon. If the BET-B had a p value of something like .10, we could still have stat sig when data from the LIVE-AIR is combined with the data from BET-B. Also, it would be nice to see the data from the patients with CRP<41mg/L. 25% of patients had a CRP<41mg/L in the LIVE-AIR and that group had 733% efficacy. When they changed the BET-B trial, they maybe should have changed the primary endpoint population to that group. The patients with CRP between 41mg/L and 150mg/L had good data in the LIVE-AIR but why not focus on the group that had 733% efficacy? And it makes sense that the patients with lower CRP would respond better because GM-CSF is upstream. Earlier is better than later when treating something upstream. Waiting too long means that the cytokine storm is already on full blast. Once the cytokine storm is on full blast, it might be too late.
Options expire this Friday. A ton of puts were sold. Whoever sold the puts has a lot of incentive to raise the share price this week. Obviously, they aren't going to get the share price back to $2.50. But the share price getting back to a $1.00 or more is realistic. The stock is oversold and a great deal at this low level so it is win-win for put sellers to buy.
jonorono
https://stocktwits.com/jonorono/message/471886032
We have not disclosed p-values except to indicate there was a signal of efficacy for primary and mortality but statistical significance was not achieved for either.
We expect NIH/NIAID will seek to publish results of its study in a peer-reviewed journal, but we cannot provide assurance this will happen or comment on timing beyond our own experience, which as you know did not occur for many months following our LIVE-AIR results.
Regards,
Ken
Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet
https://scrip.pharmaintelligence.informa.com/SC146710/Humanigen-Isnt-Throwing-In-The-Towel-On-Lenzilumab-For-COVID-19-Just-Yet
The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.
With failed NIH Covid-19 study, Humanigen CEO points to competitors' flops before FDA nods
https://endpts.com/with-failed-nih-covid-19-study-humanigen-ceo-points-to-competitors-flops-before-fda-nods/
ThoraxBMJ
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial https://t.co/WfCPZ5krb2 pic.twitter.com/SaZ01zZfgg
— ThoraxBMJ (@ThoraxBMJ) July 12, 2022
I got super excited when HGEN hit $3.52 only 10 minutes after premarket trading started this morning. 40,000 shares were traded in those 10 minutes. Crazy for premarket.
I guess we should be happy that we're keeping last week's gains on a day that the market is very red.
I've been looking at Ihub posts from the Shkreli squeeze of 2015. It is pretty interesting reading the posts as the squeeze was happening. The share price went from $.44 on November 16th to $45.82 on November 23rd. That is a 104-fold increase in one week's time.
https://investorshub.advfn.com/Humanigen-Inc-26171?nextstart=643
Anthony J Leonardi, PhD, MS
I see a major lack of scientific imagination in some people. Take this paper for instance on how gmcsf drives autoimmunity. Why have I been the only independent immunologist to claim anti gmcsf would prevent T cell apoptosis, even back in 2020? https://t.co/FFAVzDPRpo @NToola9
— AJ Leonardi, MBBS, PhD (@fitterhappierAJ) July 10, 2022
NIH posted lenzilumab's CRP peer review on their webpage today.
https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/35793833
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
https://thorax.bmj.com/content/early/2022/07/05/thoraxjnl-2022-218744
Humanigen: Topline Data for Covid-19 Treatment Expected in July; What This Could Mean for the Stock
https://www.tipranks.com/news/article/humanigen-topline-data-for-covid-19-treatment-expected-in-july-what-this-could-mean-for-the-stock/
Covid might currently not be hogging the headlines in the same manner it has done in the past couple of years, but there are still opportunities in the space for those hoping to provide long-term solutions in fighting against the virus.
One such company is Humanigen (HGEN) whose lenzilumab has been earmarked as a Covid-19 treatment and is currently being evaluated in the ACTIV-5/BET-B study; approximately 550 COVID-19 patients are participating in the trial.
Last week, the company disclosed it had been told by the NIAID/NIH that the database lock for the ACTIV-5/BET-B study has been completed. This will now enable NIH/NIAID to round off topline analysis.
“Of note,” H.C. Wainwright’s Joseph Pantginis reminds investors, “lenzilumab is the first and only anti-human GM-CSF treatment to be tested in ACTIV-5 as an accompanying therapy with remdesivir compared with placebo plus remdesivir.”
Prior to the release of the data, Pantiginis also thinks it is important to draw attention to the primary analysis of the intent to treat (ITT) group that was predetermined to include only patients under the age of 85 with a CRP less than 150 mg/L who did not need ECMO or mechanical ventilation at baseline. Additionally, the proportion of patients in the primary analysis group who died or required ventilation by day 29 is the study’s primary endpoint (the data readout should include both primary and secondary endpoints).
“This is particularly relevant,” Pantginis expounded, “because, as SARS-CoV-2 virus becomes increasingly endemic, the demand for antiviral therapies, vaccine alternatives, and variant agnostic therapies, like lenzilumab, should continue to persist and remain in high demand.”
Topline results from NIH/NIAID are anticipated to see the light of day this month. Based on feedback from the company’s recent Type B meeting with the FDA, a positive readout from the program should provide the additional data required to support an amended EUA submission for lenzilumab.
It’s evident Pantginis has high hopes regarding lenzilumab’s potential. Along with a Buy rating, the analyst gives Humanigen shares a $28 price target, which makes room for unseemly gains of 1,447% in the year ahead. (To watch Pantginis’s track record, click here)
Humanigen has plenty of support amongst Pantginis’ colleagues, too. 6 recent analyst reviews break down to 4 Buys and 1 Hold and Sell, each, all aggregating to a Moderate Buy consensus rating. Humanigen shares sell for $1.81 and have an average price target of $17.80, which suggests ~883% one-year upside potential.
A ton of puts were sold the last 2 weeks. Whoever sold the puts will have a lot of incentive to get the share price as close to $2.50 as possible. July options expire on July 15th. As a smallcap biotech, HGEN is an easily manipulatable stock as evidenced by last week's action. That manipulation should reverse and benefit us over the next 2 weeks.